Immunotherapy for childhood warts

Pediatr Ann. 2009 Jul;38(7):373-9. doi: 10.3928/00904481-20090622-06.

Abstract

Treatment-resistant warts are a common and frustrating problem for patients, parents, and providers alike. No wart treatment is uniformly effective. Indeed, well-designed randomized controlled trials are sorely needed to establish the true efficacy of all wart therapies. Treatment should be tailored to each individual patient. Although none of the immunologically-based treatments listed above (see Table, page 377) is FDA-approved for warts, they provide the treating physician with options for patients with warts that are resistant to standard treatments.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Aminoquinolines / therapeutic use
  • Antigens / therapeutic use
  • Child
  • Child, Preschool
  • Cimetidine / therapeutic use
  • Cyclobutanes / therapeutic use
  • Cyclopropanes / therapeutic use
  • Dinitrochlorobenzene / therapeutic use
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Imiquimod
  • Immunotherapy / methods*
  • Injections, Intralesional
  • Irritants / therapeutic use
  • Treatment Outcome
  • Warts / drug therapy*

Substances

  • Adjuvants, Immunologic
  • Aminoquinolines
  • Antigens
  • Cyclobutanes
  • Cyclopropanes
  • Dinitrochlorobenzene
  • Histamine H2 Antagonists
  • Irritants
  • squaric acid dibutyl ester
  • Cimetidine
  • diphenylcyclopropenone
  • Imiquimod